Pure red cell aplasia: lymphocyte inhibition of erythropoiesis

Br J Haematol. 1986 May;63(1):59-67. doi: 10.1111/j.1365-2141.1986.tb07495.x.


The pathogenesis of pure red cell aplasia (PRCA) was studied in a patient who had no evidence of malignancy. In marrow culture, no erythroid colonies (from late erythroid progenitors [CFU-E]) but normal numbers of well-haemoglobinized erythroid bursts (from early erythroid progenitors [BFU-E]) were found, indicating that BFU-E existed in the patient but that their subsequent in vivo differentiation was inhibited. Autologous coculture studies suggested that inhibition was mediated by the patient's ER + lymphocytes. After remission was induced with cyclophosphamide, autologous ER + cells no longer suppressed in vitro erythropoiesis. However, cryopreserved ER + cells, obtained with anaemia, suppressed BFU-E growth from remission marrow. An expanded population of large granular lymphocytes (LGL) with ER +, Fc gamma +, T3+, T8+, HNK-1+, Ia-, M1 -- phenotype and no functional natural killer (NK) cell activity was noted during PRCA that reverted to normal with remission. For this patient, both in vivo and in vitro evidence demonstrates a cellular inhibition of erythropoiesis at the level of differentiation between BFU-E and CFU-E.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Bone Marrow / pathology
  • Cells, Cultured
  • Colony-Forming Units Assay
  • Cyclophosphamide / therapeutic use
  • Erythrocytes / pathology
  • Erythropoiesis*
  • Female
  • Freezing
  • Humans
  • Lymphocytes / immunology*
  • Lymphocytes / pathology
  • Middle Aged
  • Red-Cell Aplasia, Pure / blood*
  • Red-Cell Aplasia, Pure / drug therapy


  • Cyclophosphamide